1 / 26

Case Management of Suspect Influenza A (H5N1) Infection in Humans

Case Management of Suspect Influenza A (H5N1) Infection in Humans. Learning Objectives. Recognize clinical features of H5N1 in humans Treatment of cases Public health action. Clinical Features. General Information. Signs and Symptoms. Laboratory Findings.

Sharon_Dale
Télécharger la présentation

Case Management of Suspect Influenza A (H5N1) Infection in Humans

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Case Management of Suspect Influenza A (H5N1) Infectionin Humans

  2. Learning Objectives • Recognize clinical features of H5N1 in humans • Treatment of cases • Public health action

  3. Clinical Features

  4. General Information

  5. Signs and Symptoms

  6. Laboratory Findings Commonly associated with avian influenza H5N1: • Drop in white blood cell count (lymphocytes) • Mild to moderate drop in blood platelet count • Increased aminotransferases (liver enzymes)

  7. Epidemiological Context

  8. Exposure to Avian Influenza • Infected poultry, particularly contact with respiratory secretions • Infected wild or pet birds • Other infected animals (e.g., pigs, cats) • Wild bird feces, poultry manure and litter containing high concentrations of virus • Contaminated surfaces

  9. Exposures Continued • Under- or uncooked poultry meat or eggs from infected birds • Contaminated vehicles, equipment, clothing, and footwear at affected sites, such as poultry farms with outbreaks • Contaminated air space (e.g., a barn, hen-house, or the air space proximal to barn exhaust fans) • Bodies of water with infected bird carcasses • Close contact with (within 3 feet of) confirmed cases Cultural context can produce unique exposures

  10. Specimen Testing

  11. Clinical Specimens for Testing Influenza A (H5N1) • Lower Respiratory Tract* • Broncheoalveolar lavage • Tracheal aspirate • Pleural fluid tap • Sputum • Upper Respiratory Tract • Nasopharyngeal swab/aspirate • Oropharyngeal swabs* • Nasal Swab * Preferred specimens

  12. Clinical Specimens for Testing • Serology • Acute and convalescent serum specimens • Acute collected within 1 week of symptom onset • Convalescent collected 2-4 weeks after symptom onset • Other infections or concurrent illness • Specimens should be collected within 3 days of symptom onset • Collect all possible specimens, serial collection

  13. Avian Influenza H5N1 Chest X-Ray Chest x-ray of an avian influenza H5N1 patient, shown by day of illness Day 5 Day 7 Day 10 Tran Tinh Hien, Nguyen Thanh Liem, Nguyen Thi Dung, et al. New England Journal of Medicine. 18 March, 2004. vol. 350 no. 12. pp 1179-1188.

  14. Treating Suspected Cases

  15. Treatment Options • Antivirals • Antibiotics • Supportive care

  16. Neuraminidase Inhibitor • Two drugs available • Oseltamivir (Tamiflu®) and Zanamivir (Relenza ®) • Should be given as soon as possible • Effective for treatment and prevention • Used for seasonal and avian influenza

  17. Other Treatments? • Amantadine and Rimantadine • H5N1 resistant in some isolates • Not as effective as neuraminidase inhibitors • Corticosteroids • Low dose for sepsis • Unclear if high dose useful • Risk of side effects • Ribavirin • Ineffective against influenza viruses

  18. Public Health Action

  19. Response Overview • Collect Case Information • Classify case according to case definition for surveillance • Facilitate specimen collection and laboratory testing • Information on avian influenza illness • Infection control measures in the home • Active case follow up • Identify close contacts and recommend chemoprophylaxis

  20. Case Definitions • Confirmed • Suspect • Report under investigation • Non-case • Refine for outbreaks

  21. Active Follow Up • Reasons for follow up • Specimens for testing • Timely notification of results • Monitor delivery of antiviral therapy • Secure antivirals if shortage • Note unusual clinical presentations or complications • Follow up by telephone • Patient • Healthcare provider (when available) • Surrogate (e.g. spouse)

  22. Identifying Close Contacts • List of contacts from patient’s case report form • Close contact = Within 3 feet • Sharing utensils, close conversation, direct contact • Follow Up • Characterize exposure • Identify signs and symptoms • Those with symptoms treated as potential avian influenza case

  23. Recommendations to Contacts No symptoms • Receive current influenza vaccine • PEP for close contacts of a confirmed avian influenza H5N1 case • Antiviral (neuraminidase inhibitor) and dosage information in Background section

  24. Instruction to Contacts No symptoms (continued) • Self monitor for 10 days after last exposure • Fever, respiratory symptoms, diarrhea, and/or conjunctivitis • Seek medical care if symptoms present • Notify public health authorities • Follow infection control measures in the home

  25. Summary • For suspect cases, ask about recent exposure and contact with humans or animals that may have had avian influenza H5N1 infection • Important appropriate clinical specimens need to be collected and tested • Begin treatment with neuraminidase inhibitor immediately! Do not wait! • Case management also means identifying contacts

  26. Breakout Groups

More Related